RA
MRNA icon

REX Advisers’s Moderna MRNA Stock Holding History

REX Advisers’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-27,100
Closed -$1.9M – 77
2026
Q2 		$1.9M Buy
+27,100
New +$1.4M 4.29% 12

Other funds holding MRNA

GAA
Green Alpha Advisors Niwot, Colorado $148M AUM 98.22% 1-Year Est. Return
FFA
Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return
GI
GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return
EB
Eastern Bank Boston, Massachusetts $6.58B AUM 23.57% 1-Year Est. Return
CI
CX Institutional Auburn, Indiana $3.69B AUM 15.82% 1-Year Est. Return
VFA
Valeo Financial Advisors Carmel, Indiana $4.74B AUM 19.15% 1-Year Est. Return
LHWM
Lake Hills Wealth Management Austin, Texas $218M AUM 31.66% 1-Year Est. Return
CA
CoreCap Advisors Southfield, Michigan $3.48B AUM 21.43% 1-Year Est. Return
TFA
Toth Financial Advisory Leesburg, Virginia $1B AUM 19.18% 1-Year Est. Return
VCM
Versant Capital Management Phoenix, Arizona $1.17B AUM 28.44% 1-Year Est. Return

REX Advisers's MRNA Position: Q3 2026 in Review

REX Advisers sold out of Moderna (MRNA) in Q3 2026, closing a stake of 27,100 shares — an estimated $1.9M sold.

REX Advisers first reported a position in MRNA in Q2 2026 and held it in 1 quarter. The position peaked at $1.9M in Q2 2026. 21 funds tracked by Wall St. Rank hold MRNA as of Q3 2026.

  • REX Advisers reported no remaining Moderna position as of Q3 2026 after selling out during the quarter.
  • REX Advisers sold 27,100 Moderna shares in Q3 2026, an estimated $1.9M.
  • REX Advisers first reported a position in Moderna in Q2 2026 and held it in 1 quarter.
  • REX Advisers's Moderna position peaked at $1.9M in Q2 2026.
  • 21 funds tracked by Wall St. Rank held Moderna as of Q3 2026.

Based on REX Advisers's 13F filing for Q3 2026, filed 8 Oct 2026.